ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1616

Vitamin D Supplementation in the Prevention of Severe Adverse Effects Caused ByGlucocorticoids: Study from the ARTESER Registry of Giant Cell Arteritis
Abstract Number: 1617

Persistence of Imaging Abnormality in Patients with Large Vessel Vasculitis Despite Clinical Remission
Abstract Number: 1618

Co-occurrence of Giant Cell Arteritis and Polymyalgia Rheumatica: Insights from a Retrospective Analysis
Abstract Number: 1619

Challenges in Managing Polymyalgia Rheumatica and Giant Cell Arteritis: Steroid Dependence and Preventive Care
Abstract Number: 1620

Unveiling of a New Molecular Imaging Biomarker? Vascular Adhesion Protein-1 and [68Ga]Ga-DOTA-Siglec-9 PET/CT in Detecting Giant Cell Arteritis Relapse
Abstract Number: 1621

Analysis of Hospitalizations of Adult Patients with Kawasaki’s Disease: A United States Population Based Study
Abstract Number: 1622

18F-FDG PET/CT in LVV During Active and Inactive Disease Phases Is Associated with the Metabolic Profile, but Not with Macrophage-related Cytokines: Results of an Integrated Analysis
Abstract Number: 1623

Sex Differences in Phenotypes and Imaging Examination in Giant Cell Arteritis: Data from the ARTESER Registry
Abstract Number: 1624

Prognostic Value of Baseline 18F-FDG PET/CT Scan in Giant Cell Arteritis with Large Vessel Involvement
Abstract Number: 1625

Impacts of a Fast-Track Referral Clinic on Health Care Utilization, Delays and Complications in Patients with Giant Cell Arteritis
Abstract Number: 1626

Intracranial Giant Cell Arteritis: A Comprehensive Systematic Review
Abstract Number: 1627

Real-World Data on Imaging Tests, Specifically Temporal Artery Ultrasound, in Giant Cell Arteritis in Japan: A Multicenter Retrospective Study
Abstract Number: 1628

Tocilizumab for Giant Cell Arteritis in Japan over 2 Years: A Multicenter Retrospective Study
Abstract Number: 1629

Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica Has a Different Vascular Ultrasound Phenotype Than Giant Cell Arteritis
Abstract Number: 1630

Disease Manifestations, Diagnostic Findings, and Mortality of 120 Consecutive Patients Suspected of Giant Cell Arteritis – Results from a Hospital GCA Fast-Track Clinic

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].